KFAS
ALNY icon

Keating Financial Advisory Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Keating Financial Advisory Services’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.8K Buy
139
+12
+9% +$3.62K 0.01% 730
2026
Q1 		$42K Buy
127
+23
+22% +$7.83K 0.01% 664
2025
Q4 		$41.4K Buy
+104
New +$46K 0.01% 695

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Keating Financial Advisory Services's ALNY Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Alnylam Pharmaceuticals (ALNY) stake by 9.4% in Q2 2026, buying an estimated $3.62K and bringing the position to 139 shares worth $41.8K. The position accounts for 0.01% of the portfolio, ranked #730.

Keating Financial Advisory Services first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $42K in Q1 2026. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Keating Financial Advisory Services held 139 shares of Alnylam Pharmaceuticals worth $41.8K as of Q2 2026.
  • Keating Financial Advisory Services bought 12 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $3.62K.
  • Alnylam Pharmaceuticals made up 0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #730 holding.
  • Keating Financial Advisory Services first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Keating Financial Advisory Services's Alnylam Pharmaceuticals position peaked at $42K in Q1 2026.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.